Jefferies upgrades AstraZeneca to “buy,” sees $80 bln sales target within reach
PositiveFinancial Markets

Jefferies has upgraded AstraZeneca to a 'buy' rating, indicating strong confidence in the company's future performance. The firm believes that AstraZeneca is on track to reach an impressive $80 billion in sales, which would mark a significant milestone for the pharmaceutical giant. This upgrade is important as it reflects the growing optimism among analysts about AstraZeneca's product pipeline and market potential, suggesting that investors may want to pay attention to this stock.
— Curated by the World Pulse Now AI Editorial System









